Aravive Inc

+0.16 (+2.84%)
Products, Strategic Combinations

Aravive Inc Says Entered Into Collaboration And License Agreement With 3D Medicines Inc On November 6

Published: 11/10/2020 13:19 GMT
Aravive Inc (ARAV) - Aravive Inc - on November 6, Entered Collaboration and License Agreement With 3d Medicines Inc.aravive Inc - Granted 3d Medicines Exclusive License to Develop and Commercialize Products That Contain Avb-500 As Sole Drug Substance.
Aravive Inc - Eligible to Receive From 3d Medicine Cash Payments of $12 Million.
Aravive Inc - Eligible to Receive From 3d Medicine Up to $207 Million in Clinical Development, Regulatory and Commercial Milestone Payments.
Aravive - 3d Medicines Will Be Solely Responsible for Development & Commercialization of Licensed Products in Mainland China, Taiwan, Hong Kong & Macau.